Skip to content

Biodistribution and dosimetry of free 118Te, an in vivo generator of the positron emitter 118Sb for long-term positron emission tomography

Oct 2026 · Physics in Medicine and Biology · Vol 71 · 0 citations
Physics Medicine

TL;DR

The limited dosimetric impact from 118Te provides justification for its use as an in vivo generator of 118Sb for long-term PET, and the ADCs reported here offer a quantitative basis for assessing the dosimetric safety of 118Te radiopharmaceuticals.

Abstract

Objective. Tellurium-118 (118Te; t1/2 = 6.00 ± 0.02 d) can act as an in vivo generator of the positron emitter antimony-118 (118Sb; t1/2 = 3.6 ± 0.3 min), enabling positron emission tomography (PET) over a week or longer. This work assessed absorbed doses associated with free 118Te to establish a dosimetric safety basis for 118Te radiopharmaceuticals. Approach. Injection solutions of free 118Te were prepared by alpha-particle irradiation of an enriched tin-116 target followed by radiochemical isolation. Ex vivo biodistribution in healthy female Slc:ICR mice was acquired at seven time points from 2 h to 29 d postinjection (n = 6 per time point). Time-integrated activity coefficients were computed from the biodistribution profiles and extrapolated to a human model using relative mass scaling. Absorbed dose coefficients (ADCs) were calculated following the medical internal radiation dose formalism with computational phantoms implemented in the dosimetry software OLINDA. Dosimetric contributions from 118Te and its coproduced radioisotopic impurity 119mTe (t1/2 = 4.69 ± 0.04 d), along with their equilibrium daughters 118Sb and 119Sb, were individually assessed. Main results. The kidneys exhibited the highest ADC in both mouse (2666.0 mGy MBq−1) and human (2.639 mGy MBq−1) models. Bone received the second-highest ADC in the mouse model, 1855.5 mGy MBq−1. Antimony-118 dominated absorbed doses across all organs examined, accounting for more than 82% of ADCs in both models. Contributions from 118Te, 119mTe, and 119Sb were minor by comparison. Significance. The kidneys and bone were identified as the primary dosimetric targets of free 118Te, with its daughter 118Sb being the principal dose contributor. The limited dosimetric impact from 118Te provides justification for its use as an in vivo generator of 118Sb for long-term PET. The ADCs reported here offer a quantitative basis for assessing the dosimetric safety of 118Te radiopharmaceuticals.

View source

Similar papers

Physics in Medicine & Biology

The kidneys and bone were identified as the primary dosimetric targets of free 118 Te, with its daughter 118 Sb being the principal dose contributor.

Jaewoong Jang, Sotaro Miyao, Xin-Di Qiu et al. · 0 citations
Open access Oct 2026

First-in-human dosimetry and biodistribution of [89Zr]Zr-oxine-labeled autologous leukocytes using PET/CT

The results support the further use of this approach for imaging autologous leukocytes using PET in a range of clinical and research settings and demonstrate the safety and favorable dosimetry of [89Zr]Zr-oxine-labeled leukocytes in healthy humans.

Kadir Gultekin, Jennifer L. Bartels, Carlos E. Cardenas et al. · 0 citations
Open access Sep 2026

Tumour-to-Kidney Absorbed Dose Ratios for Alpha-Emitter PRRTs Estimated with [177Lu]Lu-DOTATATE SPECT Images and Biokinetic Models: Patient Variations Impact Contribution from Redistributing Daughters.

The trend for tumour-to-kidney absorbed dose ratios should be weighed against other important aspects for radionuclide therapies, and considered with the uncertainty in the underlying assumption of equivalent biokinetics.

M. Kvassheim, A. Karlberg, J. Blakkisrud et al. · 0 citations
Open access Sep 2026

Biodistribution and radiation dosimetry of the PDGFRβ targeting PET tracer [68Ga]Ga-ATH001

[68Ga]Ga-ATH001 is an Affibody molecule targeting PDGFRβ in development as a Positron Emission Tomography (PET) tracer for non-invasive imaging of active fibrosis. Here we present first-in-human [68Ga]Ga-ATH001 biodistribution and radiation dosimetry data. Radiation dosimetry of [68Ga]Ga-ATH001 was evaluated in healthy...

M. Lubberink, Talakad G. Lohith, Zoltan Derdak et al. · 0 citations
Sep 2026

Evaluation of the In Vivo PET Generator 140Nd/140Pr Using a HER2-Targeting Agent.

Theranostic strategies using targeted radiopharmaceuticals frequently use f-block therapeutic radionuclides, such as 225Ac, 177Lu, and 161Tb; however, there are limited PET imaging counterparts within this chemical space. The in vivo PET generator pair 140Nd (half-life, 3.4 d; electron capture)/140Pr (half-life, 3.4 mi...

Mangi Lal Godara, V. Tekin, Hailey A. Houson et al. · 0 citations
Open access Sep 2026

In vivo Quantitative Tomography of 225Ac Daughters in a Prostate Cancer Mouse Model with a Compton Camera

Targeted alpha therapy with 225Ac is a promising modality for cancer treatment, as shown in recent preclinical and clinical studies. Preclinical imaging of 225Ac is essential to fully understand the biokinetics of developmental 225Ac radiopharmaceuticals. Although single photon emission computed tomography (SPECT) is t...

Biswajit Das, A. Bidkar, S. Naik et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.